US FDA approves first drug for fatty liver disease NASH

The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition and opening up a multi-billion opportunity.

The company's oral drug, called Rezdiffra, has been approved for patients who have NASH with fibrosis, or scarring, that has progressed to stage 2 or 3 in severity, according to an FDA label released on Thursday.

NASH, which was recently renamed metabolic dysfunction-associated steatohepatitis (MASH), affects about 1.5 million people in the United States, according to the company's estimates, but there was no approved treatment for it until now.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)